SCHEMBL4831224

SCHEMBL4831224

CN(C)CC#Cc1cnc2[nH]cc(C(=O)Cc3cccc(F)c3F)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 7/20 0.42
CYP3A4 P08684 6/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.37
DCLK1 O15075 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
NTRK1 P04629 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
CDK1 P06493 1/20 0.36
CSF1R P07333 1/20 0.36
LYN P07948 1/20 0.36
SRC P12931 1/20 0.36
MARK3 P27448 1/20 0.36
AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828081 0.82 DYRK1A (0.39) CYP2C9CYP3A4CYP2D6DCLK1DYRK3
SCHEMBL14002391 0.81 CYP2C9 (0.41) CYP2C9CYP3A4CYP2C19CYP2D6DCLK1
SCHEMBL4824095 0.81 CYP2C9 (0.41) CYP2C9CYP3A4CYP2C19CYP2D6DCLK1
SCHEMBL4831382 0.78 BRAF (0.47) CYP2C9CYP3A4CYP2D6DCLK1DYRK3
SCHEMBL4831235 0.78 AXL (0.43) CYP2C9CYP3A4CYP2D6DCLK1DYRK3
SCHEMBL4824093 0.77 BTK (0.37) CYP2C9CYP3A4CYP2C19CYP2D6DCLK1
SCHEMBL4828071 0.76 AXL (0.39) CYP2C9CYP3A4CYP2C19CYP2D6DCLK1
SCHEMBL8291682 0.76 DCLK1 (0.38) CYP2C9CYP3A4CYP2C19CYP2D6DCLK1
SCHEMBL4831421 0.75 BRAF (0.40) CYP2C9CYP3A4DCLK1DYRK3ROCK2
SCHEMBL4831413 0.74 MAP2K1 (0.50) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 CYP2C9 4732/4885CYP3A4 4783/4885CYP2C19 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.